Provention Bio, Inc. (PRVB) Income Statement Analysis

See more : Glory Sun Land Group Limited (0299.HK) Income Statement Analysis – Financial Results

Complete financial analysis of Provention Bio, Inc. (PRVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Provention Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Provention Bio, Inc. (PRVB)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.proventionbio.com

About Provention Bio, Inc.

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Metric	2022	2021	2020	2019	2018	2017
Revenue	12.90M	1.40M	0.00	0.00	0.00	0.00
Cost of Revenue	512.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	12.38M	1.40M	0.00	0.00	0.00	0.00
Gross Profit Ratio	96.03%	100.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	75.80M	69.63M	66.36M	36.36M	22.65M	7.68M
General & Administrative	64.11M	47.35M	33.33M	8.01M	4.17M	1.46M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	64.11M	47.35M	33.33M	8.01M	4.17M	1.46M
Other Expenses	627.00K	0.00	0.00	0.00	0.00	0.00
Operating Expenses	140.54M	116.97M	99.69M	44.37M	26.81M	9.14M
Cost & Expenses	141.06M	116.97M	99.69M	44.37M	26.81M	9.14M
Interest Income	2.24M	146.00K	583.00K	1.09M	669.00K	131.50K
Interest Expense	1.04M	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	3.47M	387.00K	33.00K	-16.00K	149.00K	6.50K
EBITDA	-124.69M	-115.58M	-99.69M	-44.37M	-26.67M	-9.13M
EBITDA Ratio	-966.98%	-8,285.16%	0.00%	0.00%	0.00%	0.00%
Operating Income	-128.16M	-115.58M	-99.69M	-44.37M	-26.81M	-9.14M
Operating Income Ratio	-993.88%	-8,285.16%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	1.20M	146.00K	583.00K	1.09M	149.00K	6.50K
Income Before Tax	-126.96M	-115.43M	-99.10M	-43.29M	-26.67M	-9.13M
Income Before Tax Ratio	-984.54%	-8,274.70%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	-13.39M	-1.00M	-523.00K	-1.09M	-187.00K	-131.50K
Net Income	-113.57M	-114.43M	-98.58M	-42.20M	-26.48M	-9.13M
Net Income Ratio	-880.69%	-8,203.01%	0.00%	0.00%	0.00%	0.00%
EPS	-1.52	-1.81	-1.88	-1.04	-1.18	-0.27
EPS Diluted	-1.52	-1.81	-1.88	-1.04	-1.18	-0.27
Weighted Avg Shares Out	74.72M	63.10M	52.46M	40.75M	22.44M	33.88M
Weighted Avg Shares Out (Dil)	74.72M	63.10M	52.46M	40.75M	22.44M	33.88M

Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.

April 26, 2023globenewswire.com

Hart-Scott- Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc. Paris, France – April 26 , 2023 – Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”),...

The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023

April 10, 2023247wallst.com

March was a good month for the stock market, with the S&P 500 gaining about 3.5%.

PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB

March 29, 2023businesswire.com

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Provention Bio, Inc. (NasdaqGS: PRVB) to Sanofi (NasdaqGS: SNY). Under the...

Why Provention Bio Stock Skyrocketed 256% This Week

March 16, 2023fool.com

Sanofi plans to acquire Provention Bio for around $2.9 billion. The deal will add Provention's type 1 diabetes drug Tzield to Sanofi's lineup.

Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi

March 14, 2023zacks.com

Provention Bio (PRVB) to be acquired by pharma-giant Sanofi (SNY) for $2.9 billion. The transaction is likely to close by second-quarter 2023.

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Provention Bio, Inc. - PRVB

March 14, 2023prnewswire.com

NEW YORK , March 14, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class...

This biopharma stock jumped over 250% on Monday: what happened?

March 13, 2023invezz.com

Shares of Provention Bio Inc (NASDAQ: PRVB) more than tripled on Monday after Sanofi S.A. (EPA: SAN) confirmed plans of buying the biopharmaceutical company that focused on autoimmune diseases.

Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners

March 13, 2023fool.com

Markets were mixed on a volatile day on Wall Street. Sanofi offered to buy Provention Bio at a price more than triple where the stock closed Friday.

Shareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with Sanofi

March 13, 2023prnewswire.com

MILWAUKEE , March 13, 2023 /PRNewswire/ -- Ademi LLP is investigating Provention Bio (Nasdaq: PRVB) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi. Click here to learn how to join the action https://www.ademilaw.com/case/provention-bio-inc or...